COVID-19 kidney injury twice as common as diagnosed

Publicly released:
Australia; VIC; QLD
Adobe stock
Adobe stock

A University of Queensland-led study has found millions of COVID-19 patients may have undiagnosed acute kidney injury (AKI).

Media release

From: The University of Queensland

A University of Queensland-led study has found millions of COVID-19 patients may have undiagnosed acute kidney injury (AKI).

AKI is a condition where the kidneys suddenly fail to filter waste from the blood, which can lead to serious illness or even death.

Existing data indicates approximately 20 per cent of patients admitted to hospital with COVID-19 develop AKI, rising to roughly 40 per cent for those in intensive care.

But UQ PhD candidate and kidney specialist Dr Marina Wainstein said the true numbers could be double those figures.

“Doctors look at the amount of urine a patient passes and the level of a compound called creatinine in the blood, which rises when the kidneys aren’t working well,” she said.

“However, if that creatinine rise occurs before a patient presents to hospital, we can miss the AKI diagnosis and fail to manage the patient appropriately in those early, critical days of hospitalisation.”

Dr Wainstein said when researchers also measured the fall in creatinine levels, which often follows the initial rise, the rate of AKI diagnosis in COVID-19 patients doubled.

“That was a pretty shocking finding,” she said.

Dr Wainstein said ‘missing’ AKI in COVID-19 patients is dangerous.

“Even though the AKI is already starting to improve in hospital, our research shows that these patients have worse in-hospital outcomes and are more likely to die compared to patients with no AKI,” she said.

Dr Wainstein said treatment for AKI can be as simple as checking a patient’s hydration level and stopping medications that can be toxic to the kidneys.

Study supervisor Dr Sally Shrapnel, from UQ’s School of Mathematics and Physics, said collecting and analysing data for the project during the pandemic proved challenging.

“Typically data scientists work with complete, well curated registry data, but in this project it was collected by hospital staff working under extremely onerous conditions in a variety of different resource settings,” she said.

“Curating and cleaning the data turned out to be a significant part of the project.”

Dr Shrapnel said the researchers were able to include data from resource-poor countries, where community-acquired AKI is also more common.

“These people have limited access to healthcare and are more likely to present late in the disease process.”

Dr Shrapnel said a more comprehensive definition of AKI – one which can detect cases that develop in the community - needs to be implemented as soon as possible.

“Now we have the data showing a large gap in AKI diagnosis exists, it’s time to test this definition in a clinical trial so we can identify all AKI patients early and hopefully prevent these awful outcomes.”

The research is published in PLOS Medicine.

Journal/
conference:
PLOS Medicine
Research:Paper
Organisation/s: The University of Queensland, Monash University
Funder: : In the UK this work was supported by grants from: the National Institute for Health Research (NIHR; award CO-CIN-01), the Medical Research Council (MRC; grant MC_PC_19059), the NIHR Health Protection Research Unit in Emerging and Zoonotic Infections at University of Liverpool in partnership with Public Health England (PHE), in collaboration with Liverpool School of Tropical Medicine and the University of Oxford (NIHR award 200907), UK Foreign, Commonwealth and Development Office and Wellcome (215091/Z/18/Z), Bill & Melinda Gates Foundation (OPP1209135). Internationally this work has been supported by the CIHR Coronavirus Rapid Research Funding Opportunity OV2170359, funding by the Health Research Board of Ireland [CTN-2014-12]; the Rapid European COVID-19 Emergency Response research (RECOVER) [H2020 project 101003589] and European Clinical Research Alliance on Infectious Diseases (ECRAID) [965313], the Research Council of Norway grant no 312780, and a philanthropic donation from Vivaldi Invest A/S owned by Jon Stephenson von Tetzchner; Innovative Medicines Initiative Joint Undertaking under Grant Agreement No. 115523 COMBACTE, resources of which are composed of financial contribution from the European Union’s Seventh Framework Programme (FP7/2007- 2013) and EFPIA companies, in-kind contribution; is sponsored by INSERM and funded by the REACTing (REsearch & ACtion emergING infectious diseases) consortium and by a grant of the French Ministry of Health (PHRC n˚20-0424); Stiftungsfonds zur Fo¨rderung der Beka¨mpfung der Tuberkulose und anderer Lungenkrankheiten of the City of Vienna, Project Number: APCOV22BGM; Italian Ministry of Health “Fondi Ricerca corrente– L1P6”to IRCCS Ospedale Sacro Cuore–Don Calabria; grants from Instituto de Salud Carlos III, Ministerio de Ciencia, Spain; Brazil, National Council for Scientific and Technological Development Scholarship number 303953/2018-7. MW declared funding from the University of Queensland’s Research and Training Scholarship. SM, DF, KY and SS declared funding from Artificial Intelligence for Pandemics (A14PAN) at University of Queensland. SM & SS declared funding from The Australian Research Council Centre of Excellence for Engineered Quantum Systems (EQUS, CE170100009). AN declared funding from The Health Research Board of Ireland. JL reports grants from European Commission RECOVER Grant Agreement No 101003589 and European Commission ECRAID-Base Grant Agreement 965313. JPC declared funding from US Center for Disease Control and Prevention Foundation (site PI, SCCM Discovery-PREP Covid-19 and influenza), Herrick Medical LLC (industrysponsored RCT of iv tubing modification for air-inline evacuation, ClinicalTrials.gov NCT04851782. SK declared funding from Wellcome (222410/Z/21/ Z). MGS reports grants from National Institute of Health Research UK, Medical Research Council UK, Health Protection Research Unit in Emerging & Zoonotic Infections, University of Liverpool. LM declared funding from the University of Oxford’s COVID-19 Research Response Fund. SM declared funding from Canadian Institutes of Health Research. SS declared funding from the University of Queensland Strategic funding and University of Queensland Gender Equity Grant. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. All other authors declared no specific funding for this work.
Media Contact/s
Contact details are only visible to registered journalists.